Ascendis Pharma A/S - Ordinary Share (ASND) analyst actions
Rating and price-target actions on ASND in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ASND overview →
1 measured ASND analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients | Press release | +0.73% | +0.97% |
Keep exploring
More ASND: earnings → · SEC filings → · ASND overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| RXI PHARMACEUTICALS CORP (RXII) | 477 | -1.14% | 32% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 477 | -0.11% | 46% |
| Global Cord Blood Corporation (CO) | 471 | 0.00% | 44% |
| NANTKWEST (NK) | 469 | -0.32% | 42% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.